Solomon L Woldu1, Xiaosong Meng1, Daniel Wong2, Fady Baky1, Vitaly Margulis1, Yin Xi3, Rathan M Subramaniam3,4, Aditya Bagrodia1,5. 1. Department of Urology, UT Southwestern Medical Center, Dallas, TX, United States. 2. School of Medicine, UT Southwestern Medical Center, Dallas, TX, United States. 3. Department of Radiology, UT Southwestern Medical Center, Dallas, TX, United States. 4. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States. 5. Department of Urology, University of California-San Diego, San Diego, CA, United States.
Abstract
INTRODUCTION: We aimed to determine whether anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) positron emission tomography/computed tomography (PET/CT) can accurately detect residual non-seminomatous germ cell tumor (NSGCT) prior to retroperitoneal lymph node dissection (RPLND). There is no reliable way to differentiate between fibrosis/necrosis, teratoma, and viable germ cell tumor in patients receiving post-chemotherapy RPLND. Functional imaging, including 18F-fludeoxyglucose (18F-FDG) PET/CT, has been disappointing. Due to the need for better imaging modalities, our prospective, pilot study aims to investigate the accuracy of 18F-fluciclovine PET/CT in detecting residual tumor prior to RPLND. METHODS: From March 2018 to May 2019, 10 eligible patients underwent preoperative 18F-fluciclovine PET/CT prior to undergoing bilateral, full-template RPLND or excision of mass (for one re-do RPLND) in a prospective, phase 2 study. Correlation between 18F-fluciclovine PET/CT and RPLND pathology were evaluated on a per-patient level. RESULTS: A total of 10 patients (mean age 29±7.6 years) underwent 18F-fluciclovine PET/CT prior to surgery. Nine of 10 patients received chemotherapy prior to RPLND. Correlation between 18F-fluciclovine PET/CT and RPLND pathology was seen in 3/10 (30%) patients. Five of 10 patients (50%) with negative 18F-fluciclovine PET/CT were found to have residual disease/teratoma on RPLND. Compared to the reference standard of RPLND, 18F-fluciclovine PET/CT demonstrated 29% sensitivity and 33% specificity. No patients experienced any adverse events due to 18F-fluciclovine PET/CT. CONCLUSIONS: Despite a different mechanism of action from 18F-FDG, 18F-fluciclovine has low sensitivity and specificity for residual teratoma in the retroperitoneum.
INTRODUCTION: We aimed to determine whether anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) positron emission tomography/computed tomography (PET/CT) can accurately detect residual non-seminomatous germ cell tumor (NSGCT) prior to retroperitoneal lymph node dissection (RPLND). There is no reliable way to differentiate between fibrosis/necrosis, teratoma, and viable germ cell tumor in patients receiving post-chemotherapy RPLND. Functional imaging, including 18F-fludeoxyglucose (18F-FDG) PET/CT, has been disappointing. Due to the need for better imaging modalities, our prospective, pilot study aims to investigate the accuracy of 18F-fluciclovine PET/CT in detecting residual tumor prior to RPLND. METHODS: From March 2018 to May 2019, 10 eligible patients underwent preoperative 18F-fluciclovine PET/CT prior to undergoing bilateral, full-template RPLND or excision of mass (for one re-do RPLND) in a prospective, phase 2 study. Correlation between 18F-fluciclovine PET/CT and RPLND pathology were evaluated on a per-patient level. RESULTS: A total of 10 patients (mean age 29±7.6 years) underwent 18F-fluciclovine PET/CT prior to surgery. Nine of 10 patients received chemotherapy prior to RPLND. Correlation between 18F-fluciclovine PET/CT and RPLND pathology was seen in 3/10 (30%) patients. Five of 10 patients (50%) with negative 18F-fluciclovine PET/CT were found to have residual disease/teratoma on RPLND. Compared to the reference standard of RPLND, 18F-fluciclovine PET/CT demonstrated 29% sensitivity and 33% specificity. No patients experienced any adverse events due to 18F-fluciclovine PET/CT. CONCLUSIONS: Despite a different mechanism of action from 18F-FDG, 18F-fluciclovine has low sensitivity and specificity for residual teratoma in the retroperitoneum.
Authors: J P Donohue; R G Rowland; K Kopecky; C P Steidle; G Geier; K G Ney; L Einhorn; S Williams; P Loehrer Journal: J Urol Date: 1987-06 Impact factor: 7.450
Authors: G C Toner; D M Panicek; R T Heelan; N L Geller; S Y Lin; D Bajorin; R J Motzer; H I Scher; H W Herr; M J Morse Journal: J Clin Oncol Date: 1990-10 Impact factor: 44.544
Authors: Christian Kollmannsberger; Karin Oechsle; Bernhard M Dohmen; Anna Pfannenberg; Roland Bares; Claus D Claussen; Lothar Kanz; Carsten Bokemeyer Journal: Cancer Date: 2002-05-01 Impact factor: 6.860
Authors: Gary A Ulaner; Debra A Goldman; Mithat Gönen; Hanh Pham; Raychel Castillo; Serge K Lyashchenko; Jason S Lewis; Chau Dang Journal: J Nucl Med Date: 2016-03-03 Impact factor: 10.057